Thermo Fisher ditches bid to acquire Qiagen as offer falls short
[MASSACHUSETTS] Thermo Fisher Scientific ended its agreement to purchase Qiagen after its tender offer for the Dutch health-care company fell short.
Only about 47 per cent of Qiagen shares were tendered, Thermo Fisher said in a statement Thursday, meaning the minimum threshold for acceptance of the proposed deal hadn't been met. Qiagen will pay Thermo Fisher a reimbursement of US$95 million, according to the statement.
Some shareholders had been seeking a higher price for Qiagen than the 43 euros (S$69.7) per share Thermo Fisher had offered. Davidson Kempner, a top investor in Qiagen, had said that a price between 48 euros and 52 euros a share was more appropriate and had urged others to reject Thermo Fisher's offer, which had been increased from an initial 39 euros.
BLOOMBERG
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue
Nestle sales growth sputters on US slump, vitamin snags
Hermes Q1 sales jump 17% on strong China demand
Cordlife’s independent auditor to retire after issuing disclaimer of opinion on FY2023 financials
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO